The test allows to obtain information on numerous gene regions with a simultaneous analysis on a single sample, allowing to provide important information on the genetic heterogeneity of the tumor, its molecular profile and its eventual evolution.

The purpose of the test is to characterize the mutational status of the tumoral DNA to support the diagnosis, contribute to the prognosis assessment and guide the patient in the most appropriate therapeutic choice. The test allows to investigate hotspot mutation regions of the 16 cancer-specific genes: ALK, FGFR3, KIT, PDGFRA, BRAF, HRAS, KRAS, PIK3CA, EGFR, IDH1, MET, RET, ERBB2, IDH2, NRAS and ROS1.

The analysis can be conducted on different types of tumor tissues: fresh, frozen, formalin-fixed, paraffin-embedded (FFPE) or by fine-needle aspiration (FNA).
The analysis is carried out using a certified kit for in vitro diagnostic (Myriapod NGS Cancer panel DNA, CE-IVD) that entails the amplification and sequencing through new generation techniques (NGS). The data obtained are analysed through a complex bioinformatics analysis, to identify the presence of any genetic mutations.
The test uses internal controls for the validation of the procedure and of the analytic session, it has a limit of detection of variants present with an allele frequency ≥ 5%

Results in 10 -15 working days.

Analytical sensitivity, specificity and accuracy > 99%.